• Man ≥ 18 years, who had definitive EBRT or BT for prostate cancer T1-3b, N0-1, M0

• ≥ 2 years since the end of primary radiotherapy

• PSA recurrence Phoenix criteria (nadir + 2)

• No evidence of regional lymph nodes or distant metastases on PSMA PET/CT

• MRI guided biopsy-proven local recurrence of adenocarcinoma in the prostate gland or seminal vesicles

• GTV identifiable on mpMRI

• No current endocrine therapy

• Plasma testosterone ≥1.75 nm/l

• PSA doubling time ≥ 6 months and ≤ 24 months

• Performance status 0-1

• DAN PSS score ≤ 20

• Maximal urinary flow ≥ 10 ml/s

• Life expectancy \> 5 years

• PSA ≤ 10 ug/L at recurrence